We analyzed health record and survey data of breast cancer patients who received adjuvant endocrine therapy (i.e., aromatase inhibitors vs. Tamoxifen) and identified demographic, healthcare delivery, symptomatic, and psychological characteristics associated with exposure to opioid treatments (e.g., chronic vs. nonchronic prescriptions) and race (Black vs. White). Here, CYP19A1 is linked to breast cancer.